Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

TURNOVER FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026

The board of directors (the "Board") of China Shineway Pharmaceutical Group Limited (the "Company") is pleased to announce that, the turnover of the Company and its subsidiaries (together, the "Group") for the nine months ended 30 September 2026 based on its management accounts which have not been reviewed by the auditors, was RMB 1,731 million, representing a decrease of 28.3% as compared with the same period of 2025, and in particular:

– Turnover of injection products decreased by 39.2% to RMB478 million;

– Turnover of soft capsule products decreased by 14.3% to RMB289 million;

– Turnover of granule products decreased by 10.1% to RMB351 million;

– Turnover of TCM formula granule products decreased by 30.8% to RMB503 million; and

– Turnover of products in other forms decreased by 36.9% to RMB110 million.

In terms of product mix, injection products, soft capsule products, granule products and TCM formula granule products accounted for approximately 27.6%, 16.7%, 20.3% and 29.0% of the total turnover respectively for the nine months ended 30 September 2026.

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board
China Shineway Pharmaceutical Group Limited
Lee Bun Ching Terence
Company Secretary

Hong Kong, 6 November 2026

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Mr. Li Huimin and Ms. Kang Limin; the non-executive director is Mr. Zhou Wencheng and the independent non-executive Directors are Mr. Liu Shun Fai, Mr. Yew Yat On and Ms. Wang Guihua.